Aethlon Medical merges with North Immunology, forming NewCo

Aethlon Medical: Aethlon Medical is a clinical-stage medical device company developing the Hemopurifier, an extracorporeal immunotherapeutic device designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation for applications in oncology and infectious diseases. The company maintains ongoing clinical research including oncology trials evaluating the device. In the reported development, Aethlon is entering a merger agreement with North Immunology to form a combined entity advancing a bispecific antibody program. North Immunology: North Immunology is a private biotechnology company focused on developing novel immunoregulatory therapies, including a lead bispecific antibody candidate targeting pathways relevant to inflammatory skin conditions. Incorporated recently as a Delaware entity with operations in California, it has advanced preclinical work on its immunology pipeline. Under the announced merger, North Immunology stockholders will hold the majority stake in the combined company, shifting focus to its atopic dermatitis program. Merger Structure: The transaction is structured as an all-stock merger creating a new entity that will prioritize North Immunology's bispecific antibody asset over Aethlon's legacy device program. Financing Support: An oversubscribed private placement is expected to provide capital to sustain the new company's research and development activities. Pipeline Advancement: The combined company plans to advance development of a novel IL-13 x IL-18 bispecific antibody for atopic dermatitis, with clinical studies anticipated in the coming years.